• Western blot analysis of lysates from 293 and COLO cells, using AN30A Antibody. The lane on the right is blocked with the synthesized peptide.
  • Western blot analysis of various cells using ANKRD30A Polyclonal Antibody diluted at 1:2000 cells nucleus extracted by Minute TM Cytoplasmic and Nuclear Fractionation kit (SC-003, Inventbiotech, MN, USA).

Anti-ANKRD30A antibody (1041-1090 aa) (STJ91597)

SKU:
STJ91597

Current Stock:
Host: Rabbit
Applications: WB/IHC/IF/ELISA
Reactivity: Human/Rat/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Ankyrin repeat domain-containing protein 30A (1041-1090 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
IHC 1:100-1:300
ELISA 1:5000
IF 1:50-200
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: ANKRD30A
Gene ID: 91074
Uniprot ID: AN30A_HUMAN
Immunogen Region: 1041-1090 aa
Specificity: ANKRD30A Polyclonal Antibody detects endogenous levels of ANKRD30A protein.
Immunogen: The antiserum was produced against synthesized peptide derived from the human AN30A at the amino acid range 1041-1090
Protein Name Ankyrin Repeat Domain-Containing Protein 30a
Serologically Defined Breast Cancer Antigen Ny-Br-1
Alternative Antibody Names Anti-Ankyrin Repeat Domain-Containing Protein 30a antibody
Anti-Serologically Defined Breast Cancer Antigen Ny-Br-1 antibody
Anti-ANKRD30A antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance